Sugi Predict

Sugi Predict / Compounds / SCHEMBL349057

SCHEMBL349057

SCHEMBL349057

C=C1C[C@@H]2[C@@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)CCC(=O)C=C12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 15/20 0.76
▸ ALDH1A1 P00352 3/20 0.66
▸ KDM4E B2RXH2 1/20 0.66
▸ ABCB11 O95342 1/20 0.66
▸ NR3C1 P04150 1/20 0.66
▸ PGR P06401 1/20 0.66
▸ HTR2A P28223 1/20 0.66
▸ OPRK1 P41145 1/20 0.66
▸ HTR2B P41595 1/20 0.66
▸ LMNA P02545 2/20 0.61
▸ SHBG P04278 2/20 0.61
▸ SERPINA6 P08185 2/20 0.61
▸ MAPK1 P28482 2/20 0.61
▸ HSD17B3 P37058 2/20 0.61
▸ SNCA P37840 2/20 0.61
▸ BLM P54132 2/20 0.61
▸ PMP22 Q01453 2/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ NPSR1 Q6W5P4 2/20 0.61
▸ HSD17B10 Q99714 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL349056 1.00 CYP19A1 (0.76) CYP19A1ALDH1A1KDM4EABCB11NR3C1
SCHEMBL10187417 1.00 CYP19A1 (0.76) CYP19A1ALDH1A1KDM4EABCB11NR3C1
SCHEMBL10603696 0.87 CYP19A1 (0.58) CYP19A1ALDH1A1KDM4EABCB11NR3C1
SCHEMBL42713 0.86 CYP19A1 (1.00) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL42712 0.86 CYP19A1 (1.00) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL2600419 0.86 CYP19A1 (1.00) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL3275185 0.85 CYP19A1 (0.78) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL8980388 0.85 CYP19A1 (0.55) CYP19A1ALDH1A1KDM4EABCB11NR3C1
SCHEMBL8980383 0.85 CYP19A1 (0.55) CYP19A1ALDH1A1KDM4EABCB11NR3C1
SCHEMBL1780130 0.84 CYP17A1 (0.55) CYP19A1ALDH1A1KDM4EABCB11NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010076811-A2 PROCESS FOR THE PREPARATION OF EXEMESTANE IND-SWIFT LABORATORIES LIMITED (IN) 2010-07-08 — — WO claimed
WO-2001004342-A1 PROCESS TO PREPARE EXEMESTANE PHARMACIA & UPJOHN COMPANY (US) 2001-01-18 — — WO claimed
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS TECHFIELDS PHARMA CO., LTD (CN) 2023-07-27 — — US disclosed
US-11541029-B2 High penetration compositions and their applications TECHFIELDS PHARMA CO., LTD. (CN) 2023-01-03 — — US disclosed
CN-113636965-A High penetration composition and application thereof 于崇曦 2021-11-12 — — CN disclosed
CN-107320732-B High penetration composition and application thereof 于崇曦 2021-09-07 — — CN disclosed
CN-108191846-B High penetration composition and application thereof 于崇曦 2021-08-20 — — CN disclosed
CN-112409432-A Synthesis method of exemestane 陕西理工大学 2021-02-26 — — CN disclosed
CN-111808011-A High penetration composition and application thereof 于崇曦 2020-10-23 — — CN disclosed
US-8288571-B2 Process for preparing aromatiase inhibitor exemestane CADILA HEALTHCARE LIMITED (IN) 2012-10-16 — — US disclosed
WO-2010076811-A3 PROCESS FOR THE PREPARATION OF EXEMESTANE IND-SWIFT LABORATORIES LIMITED (IN) 2012-06-14 — — WO disclosed
US-4808616-A 6-substituted androsta-1,4-diene-3,17-diones FARMITALIA CARLO ERBA S.R.L. (IT) 1989-02-28 — — US disclosed
EP-0260975-A1 4-Substituted 6- alkylidenandrostene-3,17-dione derivatives and process for their preparation FARMITALIA CARLO ERBA S.r.l. (IT) 1988-03-23 — — EP disclosed
US-4614621-A Ethynylation of 16-methylene-17-keto steroids THE UPJOHN COMPANY (US) 1986-09-30 — — US disclosed
EP-0179496-A1 16-Sulfinylmethyl-steroids, their preparation and use THE UPJOHN COMPANY (US) 1986-04-30 — — EP disclosed
US-4567001-A 16-Methylene-17α-hydroxy-progesterones THE UPJOHN COMPANY (US) 1986-01-28 — — US disclosed
EP-0148616-A2 Stabilised monolithium acetylide and the ethynylation of steroids THE UPJOHN COMPANY (US) 1985-07-17 — — EP disclosed
US-4526720-A Process to prepare stabilized monolithium acetylide THE UPJOHN COMPANY (US) 1985-07-02 — — US disclosed
EP-0104054-A2 16-methylene-steroids and their preparation THE UPJOHN COMPANY (US) 1984-03-28 — — EP disclosed
US-4322349-A Process for preparing 6-methylene steroids SCHERING AKTIENGESELLSCHAFT (DE) 1982-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541029-B2 High penetration compositions and their applications SLC19A1, HIRA, SLC43A1 CYP19A1 90/4885ALDH1A1 829/4885KDM4E 4307/4885
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS SLC5A7, SLC19A1, SLC43A1 CYP19A1 68/4885ALDH1A1 2302/4885KDM4E 2401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.